Travere Therapeutics' market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating ...

Ligand Pharma (LGND) stock gains as Citi rates the company a Buy, highlighting its underappreciated value despite its strong ...

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue ...

Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Travere Therapeutics (NasdaqGM:TVTX) ...

The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.

On Thursday, 13 November 2025, Travere Therapeutics (NASDAQ:TVTX) participated in the TD Cowen Immunology and Inflammation Summit. The company shared strategic updates on its kidney treatment ...

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, ...

New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares ...

Travere Therapeutics Inc (TVTX) stock reached a new 52-week high, closing at 36.23 USD. This milestone reflects a significant uptrend, as the company’s stock has experienced a remarkable 93.49% ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, ...

Travere Therapeutics Inc. has reached a new 52-week high, with its stock price climbing to 36.81 USD. This milestone reflects a significant upward trend for the company, which has experienced a ...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants ...